肾癌组织组蛋白去乙酰化酶1p73及血清IL―17表达临床意义.docVIP

肾癌组织组蛋白去乙酰化酶1p73及血清IL―17表达临床意义 　　[摘要] 目的 探究?I癌组织组蛋白去乙酰化酶1、p73及血清IL-17表达的临床意义。 方法 方便选取于2015年1月―2016年12月该院收治的肾癌患者80例作为肾癌组，同期入院接受血液检查的健康人20名作为健康对照组。取肾癌患者瘤体边缘无坏死的肿瘤组织作为病理标本，取瘤旁正常组织作为正常标本，运用免疫组织化学法（S-P法）将标本进行染色，统计HDAC-1及p73阳性细胞，计算阳性率；抽取肾癌患者及健康对照组静脉血，ELISA法对两组血液进行IL-17含量检测。 结果 肾癌患者的肾癌组织中HDAC-1及p73的阳性率高达81.25%和77.50%，显著高于正常肾旁组织（P0.001）；且随着临床分型的提高，HDAC-1及p73的阳性率随之提高（P0.05）；Ⅲ期和Ⅳ期肾癌患者的HDAC-1及p73的阳性率高达100.00%；Ⅰ期和Ⅱ期肾癌患者HDAC-1及p73的阳性率分别为69.56%，86.11%和56.63%，77.78%；肾癌患者血清IL-17含量随着临床分型的升高而升高，Ⅱ期、Ⅲ期、Ⅳ期肾癌患者血清IL-17含量分别高达（173.27±39.74）、（186.88±42.55）pg/mL和（189.45±15.84）pg/mL，与Ⅰ期患者相比含量显著增加（P0.05）。结论 肾癌组织HDAC-1和p73的表达显著高于肾旁正常组织，且随着临床分型的增高而增加；肾癌患者外周血中IL-17的表达显著高于健康对照组，且随着临床分型的增高而增加。提示HDAC-1、p73及IL-17可能是促进肾癌发生发展的重要因子。 　　[关键词] HDAC-1；p73；IL-7；肾癌 　　[中图分类号] R737 [文献标识码] A [文章编号] 1674-0742（2017）08（c）-0005-04 　　Clinical Significance of Renal Cell Carcinoma Histone Deacetylases 1， p73 and Serum IL-17 Expression 　　NA Ri-su 　　Department of Urinary Surgery， First Affiliated Hospital of Baotou Medical College， Baotou， Inner Mongolia， 014010 China 　　[Abstract] Objective To study the clinical significance of renal cell carcinoma histone deacetylases 1、p73 and serum IL-17 expression. Methods 80 cases of patients with renal carcinoma admitted and treated in our hospital from January 2015 to December 2016 were selected as the renal carcinoma group， 20 cases of healthy patients with blood examination at the same period were selected as the healthy control group， and the tumor tissues whose tumor margin had no necrosis were selected as the pathological specimens， and normal tissues were selected as the normal specimens， and the specimens were dyed by the ？？immunohistochemical method？， and the HDAC-1 and p73 positive cells were counted and the positive rate was calculated and the venous blood was extracted from the renal cancer patients and healthy control patients， and the IL-17 content of the two groups was tested by the ELISA method. Results The positive rates of HDAC-1 and p73 in the renal cance